Overview

Cannabidiol (CBD) for the Treatment of Social Anxiety Disorder

Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
A phase 2, multicenter, double-blind, parallel group, placebo-controlled, randomized clinical study, designed to compare the efficacy, safety, and tolerability of 2 dose levels of CBD and a matching placebo for the treatment of subjects with Social Anxiety Disorder (SAD).
Phase:
Phase 2
Details
Lead Sponsor:
EmpowerPharm Inc.
Treatments:
Cannabidiol
Pharmaceutical Solutions